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AbsTrACT
background germline pathogenic variants in SDHB/
SDHC/SDHD are the most frequent causes of inherited 
phaeochromocytomas/paragangliomas. insufficient 
information regarding penetrance and phenotypic 
variability hinders optimum management of mutation 
carriers. We estimate penetrance for symptomatic 
tumours and elucidate genotype–phenotype correlations 
in a large cohort of SDHB/SDHC/SDHD mutation carriers.
Methods a retrospective survey of 1832 individuals 
referred for genetic testing due to a personal or family 
history of phaeochromocytoma/paraganglioma. 876 
patients (401 previously reported) had a germline 
mutation in SDHB/SDHC/SDHD (n=673/43/160). tumour 
risks were correlated with in silico structural prediction 
analyses.
results tumour risks analysis provided novel 
penetrance estimates and genotype–phenotype 
correlations. in addition to tumour type susceptibility 
differences for individual genes, we confirmed that the 
SDHD:p.Pro81leu mutation has a distinct phenotype and 
identified increased age-related tumour risks with highly 
destabilising SDHB missense mutations. By Kaplan-Meier 
analysis, the penetrance (cumulative risk of clinically 
apparent tumours) in SDHB and (paternally inherited) 
SDHD mutation-positive non-probands (n=371/67 with 
detailed clinical information) by age 60 years was 21.8% 
(95% ci 15.2% to 27.9%) and 43.2% (95% ci 25.4% 
to 56.7%), respectively. risk of malignant disease at age 
60 years in non-proband SDHB mutation carriers was 
4.2%(95% ci 1.1% to 7.2%). With retrospective cohort 
analysis to adjust for ascertainment, cumulative tumour 
risks for SDHB mutation carriers at ages 60 years and 
80 years were 23.9% (95% ci 20.9% to 27.4%) and 
30.6% (95% ci 26.8% to 34.7%).
Conclusions Overall risks of clinically apparent tumours 
for SDHB mutation carriers are substantially lower 
than initially estimated and will improve counselling 
of affected families. Specific genotype–tumour risk 
associations provides a basis for novel investigative 
strategies into succinate dehydrogenase-related 
mechanisms of tumourigenesis and the development 
of personalised management for SDHB/SDHC/SDHD 
mutation carriers.
InTroduCTIon
The succinate dehydrogenase (SDH) enzyme 
complex comprises four subunits (A–D), localises 
to the inner mitochondrial membrane and catal-
yses the oxidation of succinate during the Krebs 
cycle. Three subunit genes (SDHB/SDHC/SDHD) 
are among the most important susceptibility genes 
for the neuroendocrine tumours head and neck 
paraganglioma (HNPGL) and phaeochromocytoma 
and paraganglioma (PPGL).1 2 HNPGLs are derived 
from parasympathetic-derived ganglia, whereas 
PPGLs are derived from sympathetic ganglia and 
usually secrete catecholamines. HNPGL and PPGL 
have a strong genetic basis, with approximately 
40% being associated with a germline mutation in 
one of at least 15 genes.3
Since the identification of the role of SDHB/
SDHC/SDHD in inherited PPGL/HNPGL at the 
start of this century,4–6 testing for germline muta-
tions in these genes has become part of standard 
medical practice. As testing became more wide-
spread, it was revealed that mutations in SDHC 
and SDHD were associated with a higher risk of 
HNPGL than PPGL, with the reverse for SDHB.7–10 
SDHB mutations are associated with a higher risk 
of malignancy and renal carcinoma than mutations 
in other subunits.7 10 11 Initially, the penetrance of 
SDHB mutations was estimated at ~70%–80%, and 
intensive surveillance programmes were recom-
mended, but more recent estimates suggest the 
tumour risk is <50% in non-probands.7 12–14 The 
combination of malignancy risk with incomplete 
penetrance makes designing an optimal surveil-
lance programme for asymptomatic SDHB muta-
tion carriers difficult. More accurate predictions 
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of life-time tumour risks and identification of subgroups with 
higher or lower risks would enable the development of person-
alised management and surveillance strategies.
Previously we reported the mutation spectrum and genotype–
phenotype correlations in 358 patients with germline mutations 
in SDHB and SDHD.10 Here we report the results of analysis on 
an expanded cohort of germline SDHB/SDHC/SDHD mutation 
carriers and stratify missense mutations according to predicted 
effects on structure and function. We provide more accurate 
estimates of tumour-specific risks, confirm the mutation-spe-
cific phenotype of the SDHD p.Pro81Leu mutation and iden-
tify a novel candidate genotype–phenotype association of SDHB 
missense mutations with effects on SDHB protein stability.
MATerIAls And MeThods
Patient cohort
The study sample consisted of men and women referred for 
SDHB/SDHC/SDHD mutation analysis in National Health 
Service diagnostic laboratories for a personal or family history 
of PPGL/HNPGL. Carriers of pathogenic mutations in other 
genes were excluded from this study. Clinical information was 
collected via a standard pro forma (see online supplementary 
figure 1), or clinical records, for research studies or a service 
evaluation study. Non-probands (those tested after a SDHB/S-
DHC/SDHD mutation was detected in their relative) were 
included except those with maternally inherited SDHD muta-
tions who, because of a parent of origin effect, will have a 
tumour penetrance more similar to that of the general popula-
tion.15 One proband, described previously,16 had a maternally 
inherited SDHD mutation. Affected individuals were diag-
nosed by routine clinical investigations. The work described 
was performed in accordance with the Declaration of Helsinki. 
All participants gave informed consent for genetic testing. The 
service evaluation study was approved by Birmingham Women’s 
Hospital R&D Office. A subgroup of patients (n=401) have 
been described previously6 10 14 17–19 with 358 included in Rick-
etts et al.10 We refer to patients as having ‘detailed clinical infor-
mation’ if we have received a clinical information proforma or 
have access to their records to ascertain the presence or absence, 
and age of onset, of tumours. Patients without detailed clinical 
information were those for whom we had the genetic test report 
but insufficient extra information to include them in the pene-
trance analyses (they were censored at age zero). Clinical infor-
mation was collected at the time of genetic testing and prior to 
baseline biochemical and imaging screening of asymptomatic 
gene carriers.
Molecular genetic analysis
SDHB/SDHC/SDHD mutations were detected by Sanger 
sequencing, next-generation sequencing assay20 or multiplex 
ligation-dependent probe amplification (MLPA) analysis (SALSA 
MLPA Kit P226; MRC-Holland, Amsterdam, The Netherlands) 
(details available on request).
SDHB/SDHC/SDHD sequence variants were classified as 
pathogenic/benign/variants of uncertain significance (VUS) by 
the reporting diagnostic laboratory. As methods of variant classi-
fication were not uniform between laboratories, all classifications 
were compared with the ClinVar classification,21 where avail-
able. Where there was a disagreement between the local labo-
ratory classification and the ClinVar classification, the variant 
was described as VUS. This method was chosen to minimise the 
chance of underestimating penetrance of tumours because of 
inclusion of families without a true pathogenic variant. Tumour 
risks and genotype–phenotype correlations were calculated in 
individuals with variants considered to be pathogenic or likely 
pathogenic by the diagnostic laboratory (65 probands with a 
VUS were excluded from penetrance calculations).
In silico protein structure analysis
The DUET and mCSM-PPI scoring systems22–24 were used to 
predict the structural consequences of missense mutations on 
protein stability and protein–protein affinity, respectively, using 
the models of SDHB, SDHD and the succinate complex (see 
supplementary information).
statistical analysis
Tumour risks were estimated by Kaplan-Meier analysis (SDHB/
SDHD/SDHC). All statistical tests were performed using the 
programming language R unless otherwise stated.25 The ‘survfit’ 
function from the survival package was used for Kaplan-Meier 
survival analysis and penetrance calculations. The log-rank test 
was used to compare survival distributions between cohorts of 
different genotypes. To account for the non-random ascertain-
ment of study participants with respect to their disease status, 
separate penetrance estimation analyses were carried out, in 
which we modelled the retrospective likelihood of the observed 
mutation status conditional on the disease phenotypes26 
(online supplementary material). The analysis was carried out 
in the pedigree analysis software MENDEL.27 The retrospec-
tive cohort analysis was not used for SDHD, because it does 
not address the fact that the ascertainment of SDHD mutation 
carriers considered the parental origin of the mutation. The 
0.05 level of significance was used for all tests, with Bonferroni 
correction for multiple comparisons where stated. All tests were 
two sided.
resulTs
spectrum of sdhb/sdhC/sdhd mutations
Of 1832 patients referred for genetic testing due to a personal or 
family history of PPLG/HNPGL, 1093 were probands and 1227 
had detailed clinical information available. Eight hundred seven-
ty-six had a mutation in either SDHB (n=673, probands=275), 
SDHC (n=43, probands=26) or SDHD (n=160, probands=90) 
(see online supplementary figure 2).
Copy number abnormalities (CnAs)
Forty-five probands had MLPA-detected single/multiple exon 
deletions or duplications in SDHB (n=36), SDHC (n=6) or 
SDHD (n=3) (see online supplementary table 1). Three of 36 
SDHB probands with a CNA had a single or multiexon dupli-
cation. The proportion of SDHB CNAs that were whole gene 
deletions (5.6%), exon 1 deletions (49%) and exon 3 deletions 
(14%) was similar to that in other published cohorts,8 28 29 
except for cohorts from the Netherlands where exon 3 deletions 
predominate.30 31 We found 83% (5/6) of SDHC CNAs were 
exon 6 deletions, and all three SDHD CNAs in our series were 
exon 4 deletions.
Intragenic mutations
Three hundred and forty-four probands and 436 of their rela-
tives harboured an intragenic mutation in SDHB/SDHC/SDHD 
(table 1). Forty-five intragenic mutations in 134 probands were 
reported previously.10 The ratio of mutation classes among 
probands was similar to that reported previously10 (44% 
missense, 15% nonsense, 13% splice-site, 15% frameshift, 
0.5% inframe deletions and 12% large CNAs). There were a 
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Table 1 List of all intragenic mutations found in SDHB, SDHC and SDHD
Gene Mutation Amino acid change no. of probands loVd Id59 or reference
SDHB c.17_42dup26 p.Ala15ProfsX4 1 Jafri et al14
SDHB c.72+1G>A Splice 3 LOVD ID SDHB_00171
SDHB c.72+1G>C Splice 1 Ricketts et al10
SDHB c.72+1G>T Splice 36 LOVD ID SDHB_000065
SDHB c.79C>T p.Arg27X 7 LOVD ID SDHB_000006
SDHB c.88delC p.Gln30ArgfsX47 7 LOVD ID SDHB_000017
SDHB c.118A>G p.Lys40Glu 8 LOVD ID SDHB_000018
SDHB c.136C>T p.Arg46X 11 LOVD ID SDHB_000021
SDHB c.137G>A p.Arg46Gln 22 LOVD ID SDHB_000022
SDHB c.141G>A p.Trp47X 1 LOVD ID SDHB_000023
SDHB c.166_170delCCTCA p.Pro56TyrfsX5 2 LOVD ID SDHB_000025
SDHB c.268C>T p.Arg90X 8 LOVD ID SDHB_000001
SDHB c.282_283insCTTA p.Glu95LeufsX25 3 LOVD ID SDHB_000206
SDHB c.286+2T>A Splice 1 LOVD ID SDHB_000092
SDHB c.286G>A p.Gly96Ser 6 LOVD ID SDHB_000207
SDHB c.287–1G>C Splice 1 LOVD ID SDHB_000040
SDHB c.292T>C p.Cys98Arg 1 LOVD ID SDHB_000068
SDHB c.296G>A p.Gly99Asp 1 LOVD ID SDHB_000070
SDHB c.297delC p.Ser100LeufsX4 1 LOVD ID SDHB_000208
SDHB c.298T>C p.Ser100Pro 4 LOVD ID SDHB_000089
SDHB c.302G>A p.Cys101Tyr 1 LOVD ID SDHB_000041
SDHB c.311delAinsGG p.Asn104ArgfsX15 4 LOVD ID SDHB_000071
SDHB c.325_335del11 p.Asn109LeufsX6 1 LOVD ID SDHB_000209
SDHB c.338G>A p.Cys113Tyr 3 LOVD ID SDHB_000210
SDHB c.339_352del14 p.Cys113X 1 Not described
SDHB c.343C>T p.Arg115X 6 LOVD ID SDHB_000042
SDHB c.379dupA p.Ile127AsnfsX28 7 LOVD ID SDHB_000211
SDHB c.380T>A p.Ile127Asn 2 LOVD ID SDHB_000043
SDHB c.380T>G p.Ile127Ser 21 LOVD ID SDHB_000072
SDHB c.418G>T p.Val140Phe 3 LOVD ID SDHB_000095
SDHB c.423+1G>A Splice 3 LOVD ID SDHB_000047
SDHB c.445C>T p.Gln149X 1 Not described
SDHB c.502dupC p.Gln168ProfsX11 1 LOVD ID SDHB_000075
SDHB c.526G>T p.Glu176X 1 LOVD ID SDHB_000212
SDHB c.552C>G p.Tyr184X 1 Not described
SDHB c.567_568delTG p.Ala190LeufsX3 1 Not described
SDHB c.587G>A p.Cys196Tyr 7 LOVD ID SDHB_000054
SDHB c.590C>G p.Pro197Arg 11 LOVD ID SDHB_000002
SDHB c.591delC p.Ser198AlafsX22 1 LOVD ID SDHB_000003
SDHB c.600G>T p.Trp200Cys 17 LOVD ID SDHB_000098
SDHB c.642+1G>T Splice 1 Meyer-Rochow et al60 
SDHB c.649C>T p.Arg217Cys 1 LOVD ID SDHB_000086
SDHB c.650G>T p.Arg217Leu 1 LOVD ID SDHB_000159
SDHB c.660dupT p.Asp221X 1 LOVD ID SDHB_000057
SDHB c.685_686ins13 p.Glu229AlafsX31 1 LOVD ID SDHB_000213
SDHB c.688C>G p.Arg230Gly 1 LOVD ID SDHB_000100
SDHB c.688C>T p.Arg230Cys 1 LOVD ID SDHB_000058
SDHB c.689G>A p.Arg230His 5 LOVD ID SDHB_000108
SDHB c.724C>T p.Arg242Cys 4 LOVD ID SDHB_000060
SDHB c.725G>A p.Arg242His 2 LOVD ID SDHB_000004
SDHB c.745_748dupTGCA p.Thr250MetfsX7 1 Jafri et al14 
SDHC c.1A>T Start codon mutation 3 LOVD ID SDHD_000006
SDHC c.43C>T p.Arg15X 1 LOVD ID SDHC_000013
SDHC c.77+2dupT Splice 1 Buffet et al28 
SDHC c.148C>T p.Arg50Cys 1 LOVD ID SDHC_000024
SDHC c.345dupA p.Ala116SerfsX2 1 Not described
SDHC c.378T>G p.Tyr126X 1 Not described
SDHC c.380A>G p.His127Arg 7 LOVD ID SDHC_000055
SDHC c.397C>T p.Arg133X 5 LOVD ID SDHC_000015
SDHD c.1A>G Start codon mutation 1 LOVD ID SDHD_000021
Continued
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number of recurrent mutations, for example, SDHB splice-site 
c.72+1G>T and SDHD missense c.242C>T (p.Pro81Leu) 
mutations accounted for 20% of probands, and the 10 most 
common mutations accounted for 48% (see online supplemen-
tary figure 3).
Clinical presentation
Of 297 probands with a SDHB/SDHC/SDHD mutation and 
detailed clinical information, the presenting features were 
predominantly PPGL and HNPGL, though the frequency varied 
by gene (see  online supplementary table 3). Three hundred and 
seventy-four of the 454 non-proband SDH mutation carriers 
with detailed clinical information were asymptomatic at testing.
Age-related tumour risks
Tumour risks were estimated by Kaplan-Meier analysis for all 
SDHB/SDHD/SDHC mutation carriers, probands only and 
non-probands only for SDHD non-proband carriers only those 
with paternally inherited mutations). For SDHB, retrospective 
cohort analysis was also performed using all samples combined 
(probands and non-probands), probands only and using non-pro-
bands only.
Kaplan-Meier analysis (and log-rank testing) of probands and 
non-probands (figure 1) revealed higher penetrance for symp-
tomatic tumours in SDHD than in SDHB mutation carriers 
(P=0.032), increased age-related risk of HNPGL in SDHD than 
SDHB mutation carriers (P<0.0001) and higher risk of PPGL 
in SDHB than SDHD (P=0.00019). SDHB carriers were more 
likely to develop malignant disease (P=0.0043). These findings 
remained significant when the previously reported 358 patients10 
were excluded from the analysis (data not shown).
In 34 SDHC mutation carriers with detailed clinical infor-
mation, 19 were clinically affected (15 HNPGL, 3 PPGL and 1 
had both HNPGL and PPGL). One patient with HNPGL had 
local spread and malignant features. Age-related risks of symp-
tomatic PPGL/HNPGL in SDHC were similar to that of SDHD. 
Compared with SDHB mutation carriers, SDHC carriers had 
a lower risk of PPGL (P=0.02 and P=0.06 before and after 
Bonferroni correction) and a higher risk of HNPGL (P<0.001 
after Bonferroni correction for three comparisons, log-rank test) 
(figure 1).
Overall tumour risks will be inflated by including both 
probands and non-probands (as probands always have the 
disease) so we re-estimated the cumulative risks in non-pro-
bands only. Using Kaplan-Meier analysis, the estimated risk 
of PPGL/HNPGL at age 60 years in SDHB, SDHD and SDHC 
mutation positive non-probands was 21.8% (95% CI 15.2% 
to 27.9%), 43.2% (95% CI 25.4% to 56.7%) and 25% (95% 
CI 0% to 57.0%), respectively. Nine non-probands (all 
SDHB) developed malignant disease, and the risk of malig-
nant disease at age 60 years in non-proband SDHB mutation 
carriers was 4.2% (95% CI 1.1% to 7.2%).
As expected, estimates of penetrance from the retrospec-
tive cohort analysis of a combined sample of probands and 
non-probands were lower than the above estimates from 
Kaplan-Meier analysis as the former method provides some 
adjustment for ascertainment bias. Under the retrospective 
cohort analysis, the predicted penetrance of PPGL/HNPGL 
in SDHB mutation carriers (probands and non-probands) by 
age 60 years and age 80 years was 23.9% (95% CI 20.9% 
to 27.4%) and 30.6% (95% CI 26.8% to 34.7%), respec-
tively (see figure 2), similar to the Kaplan-Meier estimates in 
non-probands.
Male SDHB mutation carriers have a higher age-related pene-
trance of PPGL/HNPGL (P=0.0034) and PPGL (P=0.0079), 
compared with women (see online supplementary figure 4), as 
calculated by Kaplan-Meier analysis and log-rank testing.
Gene Mutation Amino acid change no. of probands loVd Id59 or reference
SDHD c.14G>A p.Trp5X 2 LOVD ID SDHD_000026
SDHD c.33C>A p.Cys11X 1 LOVD ID SDHD_000027
SDHD c.36dupT p.Ala13CysfsX56 1 Not described
SDHD c.47_52+1del7 Splice 2 Not described
SDHD c.53dupC p.Leu19SerfsX50 1 Not described
SDHD c.57delG p.Leu20CysfsX66 1 LOVD ID SDHD_000080
SDHD c.64C>T p.Arg22X 2 LOVD ID SDHD_000012
SDHD c.91dupA p.Ile31AsnfsX38 1 Not described
SDHD c.94_95delTC p.Ala33IlefsX35 3 LOVD ID SDHD_000017
SDHD c.98_108del11 p.Ala33GlyfsX32 1 Not described
SDHD c.116_117insGATA p.Pro41TyrfsX29 1 Not described
SDHD c.144_145dupCA p.Ile49ThrfsX38 3 Not described
SDHD c.169+1G>A Splice 2 LOVD ID SDHD_000132
SDHD c.171delT p.Gly58AlafsX28 1 Not described
SDHD c.191_192delTC p.Leu64ProfsX4 4 LOVD ID SDHD_000013
SDHD c.205G>T p.Glu69X 1 Not described
SDHD c.242C>T p.Pro81Leu 39 LOVD ID SDHD_000003
SDHD c.242delC p.Pro81ArgfsX5 1 LOVD ID SDHD_000151
SDHD c.274G>T p.Asp92Tyr 3 LOVD ID SDHD_000004
SDHD c.276_278delCTA p.Tyr93del 2 LOVD ID SDHD_000038
SDHD c.296delT p.Leu99ProfsX36 9 LOVD ID SDHD_000040
SDHD c.325C>T p.Gln109X 2 LOVD ID SDHD_000046
SDHD c.341A>G p.Tyr114Cys 1 LOVD ID SDHD_000007
SDHD c.342T>A p.Tyr114X 2 LOVD ID SDHD_000083
The 15 mutations labelled as ‘Not described’ have, to the best of our knowledge, not been published elsewhere. 
Table 1 Continued 
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other tumours
Previously,10 we reported 12/358 patients had renal tumours 
(11 SDHB and 1 SDHD), and the updated cohort contains an 
additional four cases (all SDHB). Of 751 patients with detailed 
clinical information (584 SDHB, 33 SDHC and 134 SDHD), 15 
(2.6%) SDHB carriers and 1 (0.7%) SDHD carrier had a renal 
tumour. The risk of developing a renal tumour by age 60 years in 
SDHB mutation carriers was 4.2% (95% CI 0.46% to 7.8%) by 
Kaplan-Meier analysis of non-probands, 4.71% (95% CI 1.65% 
to 7.7%) by Kaplan-Meier analysis of all SDHB mutation carriers 
and 5.6%/3.2% (male/female) by retrospective cohort analysis of 
all SDHB mutation carriers. No further thyroid tumours were 
found beyond the three described previously in SDHB mutation 
carriers,10 giving an estimated penetrance of thyroid tumours by 
age 60 years of 1.5% (95% CI 0.0% to 3.1%) (calculated by 
Kaplan-Meier analysis of all SDHB mutation carriers). Other 
rare tumours included: (A) SDHB carriers: pituitary adenoma, 
parathyroid adenoma and pulmonary carcinoid tumour; (B) 
SDHC: pituitary adenoma, gastrointestinal stromal tumour 
(GIST); and (C) SDHD: a pituitary tumour.
Genotype–phenotype correlations
Structural prediction analysis
SDHB and SDHD missense mutations were analysed using 
DUET24 to predict their effect on protein stability and 
Figure 1 Penetrance of for clinically diagnosed disease in proband and non-proband SDHB, SDHC and SDHD mutation carriers with 95% ci 
shaded. HnPgl, head and neck paraganglioma; PPgl, phaeochromocytoma and paraganglioma.
Figure 2 Penetrance of clinical disease in SDHB mutation carriers by age 60 years, as calculated by different statistical techniques and in different 
subpopulations. HnPgl,  head and neck paraganglioma; PPgl, phaeochromocytoma and paraganglioma; rcc, renal cell carcinoma.
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mCSM-PPI to predict their effect on succinate complex forma-
tion22 (table 2).
SDHB/SDHD variants with no or uncertain pathogenicity 
were predicted by DUET to have little effect on either protein 
stability and protein complex formation (average ΔΔG −0.15 
Kcal/mol) in contrast to disease associated mutations (average 
ΔΔG −1.41 Kcal/mol) (P<0.001 two-tailed t-test).
Of the 21 disease-associated SDHB missense mutations, 20 
are predicted to be destabilising, 16 are predicted to destabilise 
the complex and 4 (p.Cys98Arg, p.Cys101Tyr, p.Cys113Tyr and 
p.Cys196Tyr) are in metal coordinating cysteines. The most desta-
bilising SDHB missense mutation, p.Ile127Ser, affected an isole-
ucine residue buried deep in the protein with a strong network 
of intramolecular hydrophobic interactions32 (figure 3A). The 
three SDHB mutations not predicted to alter protein stability 
were all predicted to affect the coordination of an iron–sulphur 
cluster, either directly or by affecting neighbourhood residues 
(figure 3B).
Table 2 DUET score for all SDHB and SDHD missense mutations described in this cohort and for rare missense variants with no or unknown 
pathogenicity
Mutation Allele frequency mCsM stability (Kcal/mol) dueT (Kcal/mol) Predicted effect
SDHB – – – – 
p.Lys40Glu Unknown −1.741 −1.774 Destabilises protomer and complex
p.Arg46Gln 0.000008238 −0.997 −1.02 Destabilises protomer
p.Gly96Ser 0.000008381 −1.024 −1.09 Destabilises protomer; positive phi glycine; affect metal binding
p.Cys98Arg Unknown 0.217 0.316 Affect metal binding; destabilse complex
p.Gly99Asp Unknown −0.989 −1.216 Destabilises protomer and complex; affect metal binding
p.Ser100Pro Unknown −0.226 −0.368 Affect metal binding; destabilse complex
p.Cys101Tyr Unknown −1.06 −1.651 Destabilises protomer; affect metal binding
p.Cys113Tyr Unknown −0.974 −1.467 Destabilises protomer and complex; affect metal binding
p.Ile127Asn Unknown −3.088 −3.213 Destabilises protomer. Mildly destabilises complex
p.Ile127Ser Unknown −3.669 −3.856 Destabilises protomer
p.Val140Phe Unknown −1.233 −1.353 Destabilises protomer. Mildly destabilises complex
p.Cys196Tyr Unknown −1.407 −1.77 Destabilises protomer and complex; affect metal binding
p.Pro197Arg Unknown −0.954 −0.784 Destabilises protomer; mildly destabilises complex; affect metal binding; loss of 
conformational restraint
p.Trp200Cys Unknown −1.442 −1.205 Destabilises protomer and complex
p.Arg217Cys Unknown −1.916 −1.948 Destabilises protomer and complex
p.Arg217Leu Unknown −1.031 −0.879 Destabilises protomer and complex
p.Arg230Gly Unknown −1.848 −2.45 Destabilises protomer and complex
p.Arg230Cys 0.000008252 −1.739 −1.836 Destabilises protomer and complex
p.Arg230His Unknown −1.903 −2.133 Destabilises protomer
p.Arg242Cys Unknown −1.386 −1.619 Destabilises protomer; mildly destabilises complex; affect metal binding
p.Arg242His 0.00002471 −1.948 −2.035 Destabilises protomer; mildly destabilises complex; affect metal binding
SDHD – – – – 
p.Pro81Leu Unknown −0.297 0.036 Destabilising  transmembrane
p.Asp92Tyr Unknown −0.907 −0.868 Destabilising transmembrane
p.Tyr114Cys Unknown 0.236 0.388 Stabilising
Mutations with no or unknown pathogenicity 
Mutation Allele frequency mCsM dueT Predicted effect
SDHB – – – – 
p.Ala3Gly 0.00436 −0.28 −0.244 Neutral
p.Thr17Ala Unknown −0.943 −0.82 Destabilising
p.Cys22Ser 0.0001331 0.119 0.135 Neutral
p.Arg27Gly 0.00004183 −0.229 −0.208 Neutral
p.His57Arg 0.0007249 −0.238 0.011 Neutral
p.Ser100Phe Unknown −0.226 −0.368 Neutral
p.Ser163Pro 0.01254 −0.136 −0.03 Introduction of a conformational restraint
SDHD – – – – 
p.Gly12Ser 0.007268 −0.377 −0.134 Altered localisation
p.Arg17Leu Unknown 0.549 0.481 Mildly stabilising
p.Ile40Val 0.00003295 −0.461 −0.182 Neutral
p.Glu42Ala Unknown −0.255 −0.017 Neutral
p.His50Arg 0.006515 −0.4 −0.155 Altered localisation
p.Pro87His Unknown −0.571 −0.442 Neutral
p.His145Asn Unknown −0.055 0.018 Neutral
Allele frequencies are as reported in the ExAC database (Exome Aggregation Consortium, Cambridge, Massachusetts, USA), all ethnicities, accessed 17 June 201761
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Structure–phenotype correlations and mutation specific phenotypes
We confirmed our previous observation10 that the SDHD 
p.Pro81Leu phenotype is distinct from that of other 
SDHD mutation carriers, with a low PPGL risk (figure 4). 
Of 53 individuals with detailed clinical information, 15 
were asymptomatic, 37 had HNPGL (two metastatic) and 
1 had PPGL (described previously by Yeap et al).16 The 
p.Pro81Leu mutation is predicted to have a very mild effect 
on protein stability. Excluding the cases originally analysed 
by Ricketts et al10 to create a replication cohort confirmed 
the lower risk of PPGL in SDHD p.Pro81Leu mutation 
carriers versus other SDHD mutation carriers (P=0.031, 
data not shown).
There were no differences in age-related risks of PPGL/
HNPGL between missense and truncating variants (data not 
shown). However, there was a higher overall penetrance for 
clinical disease (all tumour risk) (P=0.0047) and PPGL risk 
(P=0.00024) in p.Ile127Ser mutation carriers (the missense 
mutation with the highest DUET score for predicted protein 
instability) compared with other missense mutations. 
Furthermore, using the surv_cutpoint() function in R, which 
is designed to use the maximally selected rank statistics from 
the ‘maxstat’ R package to find the optimum cutpoint for 
continuous variables, the PPGL/HNPGL and PPGL risks 
were significantly higher for those missense mutations 
with the most destabilising DUET scores (PPGL/HNPGL 
penetrance: P=0.0086; PPGL penetrance: P=0.00025). 
The significance of these differences was preserved when 
calculated for probands only (PPGL/HNPGL penetrance: 
P=0.021; PPGL penetrance: P=0.0051, see figure 5).
dIsCussIon
To our knowledge, this is the largest series of SDHB/SDH-
C/SDHD mutation carriers yet reported (see  online supplemen-
tary tables 2 and 4) and the previous largest cohort from Buffet 
et al28 (363 probands, 269 with SDHB/C/D mutations), which 
did not report genotype–phenotype correlations. Our large-scale 
comprehensive genotype–phenotype assessments uncovered a 
series of novel observations:
Figure 3 (a) the isoleucine reside at position 127 of SDHB is buried in the middle of the structure, making a network of strong intramolecular 
hydrophobic interactions. Mutation to serine would introduce a polar residue and disrupt all of these important contacts. (B) One of three iron–sulphur 
clusters in SDHB, coordinated by four cysteine residues. Four of these (cys98, cys101, cys113 and cys196) are mutated in our cohort.
Figure 4 Penetrance of clinical disease in proband and non-proband SDHD p.Pro81leu mutation carriers versus all other SDHD mutation carriers with 
95% ci marked. P values are for the log-rank test comparing the survival distributions of SDHD p.Pro81leu and all other SDHD mutation carriers. HnPgl,   
head and neck paraganglioma; PPgl, phaeochromocytoma and paraganglioma.
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Gene-specific and mutation-specific differences in penetrance 
and expression
We unequivocally confirmed that SDHD mutation carriers had a 
higher overall penetrance for symptomatic tumours and a higher 
risk of HNPGL compared with SDHB, whereas SDHB mutation 
carriers had a higher risk of malignancy and were significantly 
more likely to develop PPGL. We have confirmed the findings 
of Jochmanova et al33 that male SDHB mutation carriers are at 
higher risk of disease than females (calculated by Kaplan-Meier 
analysis and log-rank testing). The reason for this observation 
is not clear. Although it is possible that because asymptomatic 
female at risk relative might be more likely to come forward for 
predictive genetic testing than males we note that in our cohort, 
there were more male than female probands with SDHB muta-
tions (153 male, 110 female), and there were equal numbers of 
male and female non-probands with SDHB mutations (198 male, 
201 female). Of the unaffected at risk relatives without a muta-
tion (relatives of SDHB/D/C mutation carriers), 130 were female 
and just 103 were male.
The phenotype associated with SDHC mutations has not been 
well defined. Early reports described benign HNPGLs,5 34 35 
but more recent studies have also identified extra-adrenal para-
gangliomas and more invasive tumours. Bickmann et al36 and 
Bourdeau et al37 both describe SDHC p.Arg133X mutation 
carriers (a mutation that is also common in our cohort) presenting 
with extra-adrenal paragangliomas and HNPGLs, both benign 
and malignant. Our findings of SDHC mutation carriers with 
extra-adrenal paragangliomas, pheochromocytoma and a case 
of HNPGL with malignant features are consistent with similar 
tumour risks with SDHC and paternally inherited SDHD 
mutations (Lefebvre and Foulkes38 recommend similar tumour 
screening for SDHC and SDHD mutation carriers).
We replicated our previous finding that SDHD p.Pro81Leu 
mutation carriers manifest almost exclusively with HNPGL, 
while other SDHD mutation types predispose to both HNPGLs 
and PPGLs. From a clinical perspective, it can be proposed 
that SDHD p.Pro81Leu mutation carriers do not need inten-
sive imaging for PPGL. Although the risk of PPGL in SDHD 
p.Pro81Leu mutation carriers was not zero, the single patient 
with a phaeochromocytoma was highly unusual16 and was the 
only example of tumour development after maternal inheritance 
of a SDHD mutation. Interestingly, all of the rare cases of tumours 
in individuals with maternally inherited SDHD mutations have 
been phaeochromocytomas and none have had a HNPGL.16 39 40 
SDHD has a key role in anchoring the SDH complex to the 
inner mitochondrial membrane, and a truncating SDHD muta-
tion would inactivate the function of the entire SDH complex 
and be predicted to lead to disordered signalling in the hypoxic 
gene response pathway and to epigenetic abnormalities resulting 
from inhibition of enzymes such as prolyl-hydroxylases and 
ten-eleven translocation enzymes.41–44 The SDHD p.Pro81Leu 
mutation is predicted not to cause protein instability but to inter-
fere with ubiquinone metabolism/electron transport by changing 
the folding of helix 1S and by destroying a ubiquinone binding 
site.10 45 The small risk of PPGL with the p.Pro81Leu mutations 
suggests that PPGL and HNPGL result from impairment of 
different aspects of the function of the SDH complex.
Our in silico analysis of the structural effects of SDHB missense 
mutations revealed a novel genotype–phenotype association in 
which the missense mutations predicted to have the greatest 
protein destabilising effects were associated with a higher 
penetrance and risk of PPGL. If these findings are confirmed, 
they could be used to stratify tumour surveillance programmes 
according to individual mutation risks. They could complement 
other methods, such as tumours studies and in vitro functional 
studies in human tissues or model organisms such as yeast,46 to 
elucidate the molecular mechanisms and clinical significance of 
the mutation.
other tumours
We also found a variety of rarer tumour types in individuals with 
SDHB/SDHC/SDHD mutations, including renal cell carcinoma 
(RCC), GIST, thyroid and pituitary tumours.7 10 47–51 The highest 
risk for RCC is in SDHB mutation carriers (though they can 
occur in SDHD and SDHC mutation carriers), and we estimated 
Figure 5 Penetrance of clinical disease in SDHB missense mutation carrier probands, split by with more stabilising (more negative) and less destabilising 
(less negative) DUet scores. the maximally selected rank statistics from the ‘maxstat’ r package was used to find the optimum cutpoint for DUet score, and 
the number of probands in the DUet score groups for each analysis is displayed in ‘number at risk’ tables below each plot. the optimum cutpoints for DUet 
score were −1.21 for PPgl risk and for PPgl/HnPgl risk, −0.88 for HnPgl risk and −1.02 for malignancy risk. HnPgl,   head and neck paraganglioma; 
PPgl, phaeochromocytoma and paraganglioma.
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the risk of RCC by age 60 years in SDHB carriers is 4.7% (95% 
CI 1.6% to 7.7%) by Kaplan-Meier analysis of probands and 
non-probands and 5.63%/3.18% (male/female risk) by retro-
spective cohort analysis.
Although the risk of renal tumours is smaller than for PPGL, 
if abdominal imaging is being performed for PPGL, it is straight-
forward to incorporate renal imaging. Our results suggest that 
thyroid imaging is not indicated if asymptomatic.
Penetrance in non-probands
Accurate knowledge of the natural history of a disease is 
required for optimum management. For rare diseases, there 
may be limited numbers of affected individuals, and ascertain-
ment bias in research studies can result in over-representation of 
extreme phenotypes with overestimation of disease risks. Inter-
estingly, with wider application of SDHB/C/D genetic testing, 
penetrance estimates for SDHB mutation carriers have declined. 
Original methods used Kaplan-Meier analysis of both probands 
and non-probands and produced penetrance estimates such as 
75% by age 50 years,7~55% by age 50 years12 and 50% by 
age 50 years.10 Subsequently, analyses have been published that 
have controlled for ascertainment bias by excluding probands, 
producing estimates more like 20% by age 50 years.14 33 An alter-
native approach has been to study a single large family so that 
the majority of patients analysed are non-probands, producing 
penetrance estimates of 35% by age 40 years52 and 26% by age 
48.53 More recently, the use of maximum likelihood methods to 
control for ascertainment bias has resulted in estimates of pene-
trance as low as 13%,13 9%54 and 21%55 at age 50 years.
The above cohorts have ranged in size from 15 to 344 SDHB 
mutation carriers. To better understand the prognosis for in indi-
viduals undergoing predictive testing, we tested a large (n=584 
with detailed clinical information) cohort of SDHB mutation 
carriers, adjusting for ascertainment bias using two approaches. 
We estimated overall clinical penetrance and tumour-specific 
risks by Kaplan-Meier analysis after excluding probands and 
compared the estimates with those obtained by retrospective 
cohort analysis in SDHB mutation carriers. We estimated clin-
ical disease penetrance in non-proband SDHB mutation carriers 
at 50 years, 60 years and 80 years to be 16%, 22% and 44%, 
respectively, and these were similar with the retrospective cohort 
analysis estimates: cumulative risk of 24% for PPLG/HNPGL by 
age 60 years and 31% by age 80 years. One limitation to our 
analysis was that the unavailability of pedigree structures that 
would have allowed us to look for potential parent-of-origin 
effects and to fully adjust for ascertainment.
The recent demonstrations of lower tumour risks raise 
important questions regarding follow-up for asymptomatic 
SDHB mutation carriers. Blood/urine biochemical analysis to 
detect metanephrines is inexpensive, but the risk of non-secre-
tory and malignant PPGL/HNPGL and renal and GIST tumours 
would argue for regular imaging. The Endocrine Society guide-
lines56 recommend annual biochemistry with urine or plasma 
metanephrines and 2 yearly cross-sectional imaging using either 
CT/MRI of skull base, neck, thorax abdomen and pelvis. It 
should be noted that the our tumour risk estimates are for clin-
ically apparent disease and are censored at the time of genetic 
testing. Subsequently, asymptomatic mutation carriers will 
have undergone biochemical and radiological surveillance and, 
though this information was not available, some may have been 
found to have an asymptomatic tumour. Thus, in a study of 30 
SDHx mutation carriers,57 a tumour was detected in one patient 
after 1 year follow-up from normal baseline imaging. Tufton 
et al58 describe a cohort of 65 asymptomatic SDHB mutation 
carriers undergoing surveillance by MRI. They found that 25% 
of these patients had a likely SDH-related tumour identified 
after baseline imaging or after a further 2–6 years of screening. 
The penetrance estimates for clinically apparent tumours in our 
study will be lower than those estimated in studies where patients 
have completed comprehensive screening and follow-up but 
are comparable with those from other large cohort studies and 
are consistent with more recent, although smaller, studies (see 
above) that have concluded that SDHB mutations are not asso-
ciated with a high lifetime risk for clinically apparent tumours. 
Although the non-inclusion of asymptomatic screen-detected 
lesions might be viewed as a limitation of the study design, it 
does avoid the uncertainties regarding whether asymptomatic 
tumours would become symptomatic, and the risk estimates 
for clinically apparent tumours are highly relevant to patients 
wishing to know their lifetime risks of having a symptomatic 
tumour.
In the light of the robust data from this and other studies 
demonstrating lower than previously estimated tumour risks in 
SDHB non-proband mutation carriers, there is a pressing need 
to continue to systematically collect data on the outcome of 
surveillance programmes. It is also highly relevant to develop 
strategies to enable patient stratification (eg, individuals at high 
risk because of specific mutations or family history/genetic modi-
fiers) and to enable non-invasive early detection of tumours.
Author affiliations
1Department of Medical genetics, University of cambridge and niHr cambridge 
Biomedical research centre and cancer research UK cambridge cancer centre and 
cambridge University Hospitals nHS Foundation trust, cambridge, UK
2Department of Biochemistry, University of cambridge, cambridge, UK
3Department of Biochemistry and Molecular Biology, Bio21 institute, University of 
Melbourne, Melbourne, Victoria, australia
4instituto rené rachou, Fundação Oswaldo cruz, Belo Horizonte, Brazil
5Department of Public Health and Primary care, University of cambridge, cambridge, 
UK
6West Midlands regional genetics service, Birmingham Women’s Hospital, 
Birmingham, UK
7Department of clinical genetics, Queen elizabeth University Hospital, glasgow, UK
8Yorkshire regional genetics Service, St. James’s University Hospital, leeds, UK
9Department of endocrinology, King’s college Hospital, london, UK
10northern genetics Service, newcastle upon tyne Hospitals nHS Foundation trust, 
newcastle upon tyne, UK
11Peninsula clinical genetics Service, royal Devon & exeter Hospital, exeter, UK
12Department of clinical genetics, Sheffield children’s Hospital, Sheffield, UK
13Department of clinical genetics, St Michael’s Hospital, Bristol, UK
14Department of clinical genetics, liverpool Women’s nHS Foundation trust, 
liverpool, UK
15Department of Medical genetics, St. george’s University of london, london, UK
16Queen elizabeth Medical centre, Queen elizabeth Hospital, Birmingham, UK
17Manchester centre for genomic Medicine, St Mary’s Hospital, central Manchester 
University Hospitals nHS Foundation trust, Manchester, UK
18east of Scotland regional genetics Service, ninewells Hospital and Medical School, 
Dundee, UK
19northern ireland regional genetics Service, Belfast city Hospital, Belfast Health & 
Social care trust, Belfast, UK
20Department of clinical genetics, addenbrooke’s treatment centre, cambridge 
University Hospitals nHS Foundation trust, cambridge, UK
21the Wolfson Diabetes and endocrine clinic, institute of Metabolic Science, 
cambridge University Hospitals nHS Foundation trust, cambridge, UK
22Department of clinical genetics, guy’s Hospital, london, UK
23institute of cardiovascular & Medical Sciences, University of glasgow, glasgow, 
Scotland
Acknowledgements We would like to thank the patients and the many clinicians 
and clinical laboratory scientists who contributed to this research. We apologise to 
researchers whose work we have not cited because of space limitations.
Contributors erM conceived, designed and supervised the study. Kaa collected 
the data and performed the Kaplan-Meier analysist. DBa and DeVP produced the in 
silico structural prediction analysis. DrB and aca performed the retrospective cohort 
group.bmj.com on March 20, 2018 - Published by http://jmg.bmj.com/Downloaded from 
10 Andrews KA, et al. J Med Genet 2018;0:1–11. doi:10.1136/jmedgenet-2017-105127
Cancer genetics
analysis calculations. the remaining authors clinically characterised the patients at 
their respective centres. all authors were involved in drafting the article or revising 
it critically for important intellectual content and in the final approval of the version 
to be submitted. Kaa and erM wrote the first draft of the paper and are responsible 
for the overall content as guarantors.
Funding this work was supported by the east anglian Foundation Programme (to 
Kaa), the University of cambridge (Kaa), niHr cambridge Biomedical research 
centre (Kaa and erM), cancer research UK cambridge cancer centre (erM), 
european research council advanced researcher award (erM), British Heart 
Foundation (eM), niHr Senior investigator award (erM), newton Fund rcUK-
cOnFaP grant awarded by the Medical research council (Mrc), Fundação de 
amparo à Pesquisa do estado de Minas gerais (FaPeMig) (to DeVP and DBa), 
nHMrc cJ Martin Fellowship (aPP1072476) and Jack Brockhoff Foundation (JBF 
4186, 2016) (to DBa), instituto rené rachou (cPqrr/FiOcrUZ Minas) and conselho 
nacional de Desenvolvimento científico e tecnológico (cnPq) (to DeVP), Health 
research Board ireland (rtc) and cancer research – UK grant c12292/a20861 
(to aca). the University of cambridge has received salary support in respect of eM 
from the nHS in the east of england through the clinical academic reserve. the 
views expressed are those of the authors and not necessarily those of the nHS or 
Department of Health.
disclaimer the funding agencies had no role in study design, data collection or 
analysis or writing of the article.
Competing interests none declared.
Patient consent Obtained.
ethics approval South Birmingham research ethics committee.
Provenance and peer review not commissioned; externally peer reviewed.
open Access this is an Open access article distributed in accordance with the 
terms of the creative commons attribution (cc BY 4.0) license, which permits others 
to distribute, remix, adapt and build upon this work, for commercial use, provided 
the original work is properly cited. See: http:// creativecommons. org/ licenses/ by/ 4. 0/
© article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. all rights reserved. no commercial use is permitted unless otherwise 
expressly granted.
reFerenCes
 1 Maher er. Phaeochromocytoma and paraganglioma: next-generation sequencing and 
evolving Mendelian syndromes. Clin Med 2014;14:440–4.
 2 Favier J, amar l, gimenez-roqueplo aP. Paraganglioma and phaeochromocytoma: 
from genetics to personalized medicine. Nat Rev Endocrinol 2015;11:101–11.
 3 toledo ra, Burnichon n, cascon a, Benn De, Bayley JP, Welander J, tops cM, Firth 
H, Dwight t, ercolino t, Mannelli M, Opocher g, clifton-Bligh r, gimm O, Maher 
er, robledo M, gimenez-roqueplo aP, Dahia Pl; ngS in PPgl (ngSnPPgl) Study 
group. consensus Statement on next-generation-sequencing-based diagnostic 
testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol 
2017;13:233–47.
 4 Baysal Be, Ferrell re, Willett-Brozick Je, lawrence ec, Myssiorek D, Bosch a, van der 
Mey a, taschner Pe, rubinstein WS, Myers en, richard cW, cornelisse cJ, Devilee 
P, Devlin B. Mutations in SDHD, a mitochondrial complex ii gene, in hereditary 
paraganglioma. Science 2000;287:848–51.
 5 niemann S, Müller U. Mutations in SDHc cause autosomal dominant paraganglioma, 
type 3. Nat Genet 2000;26:268–70.
 6 astuti D, latif F, Dallol a, Dahia Pl, Douglas F, george e, Sköldberg F, Husebye eS, eng 
c, Maher er. gene mutations in the succinate dehydrogenase subunit SDHB cause 
susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J 
Hum Genet 2001;69:49–54.
 7 neumann HP, Pawlu c, Peczkowska M, Bausch B, McWhinney Sr, Muresan M, 
Buchta M, Franke g, Klisch J, Bley ta, Hoegerle S, Boedeker cc, Opocher g, Schipper 
J, Januszewicz a, eng c; european-american Paraganglioma Study group. Distinct 
clinical features of paraganglioma syndromes associated with SDHB and SDHD gene 
mutations. JAMA 2004;292:943–51.
 8 Burnichon n, rohmer V, amar l, Herman P, leboulleux S, Darrouzet V, niccoli P, 
gaillard D, chabrier g, chabolle F, coupier i, thieblot P, lecomte P, Bertherat J, 
Wion-Barbot n, Murat a, Venisse a, Plouin PF, Jeunemaitre X, gimenez-roqueplo 
aP; Pgl.net network. the succinate dehydrogenase genetic testing in a large 
prospective series of patients with paragangliomas. J Clin Endocrinol Metab 
2009;94:2817–27.
 9 Mannelli M, castellano M, Schiavi F, Filetti S, giacchè M, Mori l, Pignataro V, 
Bernini g, giachè V, Bacca a, Biondi B, corona g, Di trapani g, grossrubatscher e, 
reimondo g, arnaldi g, giacchetti g, Veglio F, loli P, colao a, ambrosio Mr, terzolo 
M, letizia c, ercolino t, Opocher g; italian Pheochromocytoma/Paraganglioma 
network. clinically guided genetic screening in a large cohort of italian patients 
with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin 
Endocrinol Metab 2009;94:1541–7.
 10 ricketts cJ, Forman Jr, rattenberry e, Bradshaw n, lalloo F, izatt l, cole tr, 
armstrong r, Kumar VK, Morrison PJ, atkinson aB, Douglas F, Ball Sg, cook J, 
Srirangalingam U, Killick P, Kirby g, aylwin S, Woodward er, evans Dg, Hodgson SV, 
Murday V, chew Sl, connell JM, Blundell tl, Macdonald F, Maher er. tumor risks and 
genotype-phenotype-proteotype analysis in 358 patients with germline mutations in 
SDHB and SDHD. Hum Mutat 2010;31:41–51.
 11 ricketts c, Woodward er, Killick P, Morris Mr, astuti D, latif F, Maher er. 
germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 
2008;100:1260–2.
 12 Benn De, gimenez-roqueplo aP, reilly Jr, Bertherat J, Burgess J, Byth K, croxson M, 
Dahia Pl, elston M, gimm O, Henley D, Herman P, Murday V, niccoli-Sire P, Pasieka 
Jl, rohmer V, tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, robinson Bg. clinical 
presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin 
Endocrinol Metab 2006;91:827–36.
 13 Schiavi F, Milne rl, anda e, Blay P, castellano M, Opocher g, robledo M, cascón 
a. are we overestimating the penetrance of mutations in SDHB? Hum Mutat 
2010;31:761–2.
 14 Jafri M, Whitworth J, rattenberry e, et al. evaluation of SDHB, SDHD and VHl 
gene susceptibility testing in the assessment of individuals with non-syndromic 
phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin 
Endocrinol 2013;78:898–906.
 15 Hoekstra aS, addie rD, ras c, Seifar rM, ruivenkamp ca, Briaire-de Bruijn iH, Hes FJ, 
Jansen Jc, corssmit eP, corver We, Morreau H, Bovée JV, Bayley JP, Devilee P. Parent-
of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-
linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers. 
Hum Mol Genet 2016;25:3715–28.
 16 Yeap PM, tobias eS, Mavraki e, Fletcher a, Bradshaw n, Freel eM, cooke a, Murday 
Va, Davidson Hr, Perry cg, lindsay rS. Molecular analysis of pheochromocytoma 
after maternal transmission of SDHD mutation elucidates mechanism of parent-of-
origin effect. J Clin Endocrinol Metab 2011;96:e2009–e2013.
 17 astuti D, Hart-Holden n, latif F, lalloo F, Black gc, lim c, Moran a, grossman aB, 
Hodgson SV, Freemont a, ramsden r, eng c, evans Dg, Maher er. genetic analysis 
of mitochondrial complex ii subunits SDHD, SDHB and SDHc in paraganglioma and 
phaeochromocytoma susceptibility. Clin Endocrinol 2003;59:728–33.
 18 armstrong r, greenhalgh Kl, rattenberry e, Judd B, Shukla r, losty PD, Maher 
er. Succinate dehydrogenase subunit B (SDHB) gene deletion associated with a 
composite paraganglioma/neuroblastoma. J Med Genet 2009;46:215–6.
 19 Henderson a, Douglas F, Perros P, Morgan c, Maher er. SDHB-associated 
renal oncocytoma suggests a broadening of the renal phenotype in hereditary 
paragangliomatosis. Fam Cancer 2009;8:257–60.
 20 rattenberry e, Vialard l, Yeung a, Bair H, McKay K, Jafri M, canham n, cole tr, 
Denes J, Hodgson SV, irving r, izatt l, Korbonits M, Kumar aV, lalloo F, Morrison PJ, 
Woodward er, Macdonald F, Wallis Y, Maher er. a comprehensive next generation 
sequencing-based genetic testing strategy to improve diagnosis of inherited 
pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013;98:e124
8–e1256.
 21 landrum MJ, lee JM, Benson M, Brown g, chao c, chitipiralla S, gu B, Hart J, 
Hoffman D, Hoover J, Jang W, Katz K, Ovetsky M, riley g, Sethi a, tully r, Villamarin-
Salomon r, rubinstein W, Maglott Dr. clinVar: public archive of interpretations of 
clinically relevant variants. Nucleic Acids Res 2016;44:D862–D868.
 22 Pires De, ascher DB, Blundell tl. mcSM: predicting the effects of mutations in 
proteins using graph-based signatures. Bioinformatics 2014;30:335–42.
 23 Pires De, chen J, Blundell tl, ascher DB. in silico functional dissection of saturation 
mutagenesis: interpreting the relationship between phenotypes and changes in 
protein stability, interactions and activity. Sci Rep 2016;6:19848.
 24 Pires De, ascher DB, Blundell tl. DUet: a server for predicting effects of mutations 
on protein stability using an integrated computational approach. Nucleic Acids Res 
2014;42:W314–W319.
 25 r core team. R: A Language and Environment for Statistical Computing. Vienna, 
australia: r Foundation for Statistical computing, 2017.
 26 Barnes Dr, lee a, easton DF, antoniou ac. eMBrace investigators, kconFab 
investigators. evaluation of association methods for analysing modifiers of disease 
risk in carriers of high-risk mutations. Genet Epidemiol 2012;36:274–91.
 27 lange K, Weeks D, Boehnke M, Maccluer JW, Maccluer JW. Programs for Pedigree 
analysis: MenDel, FiSHer, and dgene. Genet Epidemiol 1988;5:471–2.
 28 Buffet a, Venisse a, nau V, roncellin i, Boccio V, le Pottier n, Boussion M, travers c, 
Simian c, Burnichon n, abermil n, Favier J, Jeunemaitre X, gimenez-roqueplo aP. a 
decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. 
Horm Metab Res 2012;44:359–66.
 29 neumann HP, erlic Z, Boedeker cc, rybicki la, robledo M, Hermsen M, Schiavi F, 
Falcioni M, Kwok P, Bauters c, lampe K, Fischer M, edelman e, Benn De, robinson 
Bg, Wiegand S, rasp g, Stuck Ba, Hoffmann MM, Sullivan M, Sevilla Ma, Weiss MM, 
Peczkowska M, Kubaszek a, Pigny P, Ward rl, learoyd D, croxson M, Zabolotny D, 
Yaremchuk S, Draf W, Muresan M, lorenz rr, Knipping S, Strohm M, Dyckhoff g, 
Matthias c, reisch n, Preuss SF, esser D, Walter Ma, Kaftan H, Stöver t, Fottner c, 
gorgulla H, Malekpour M, Zarandy MM, Schipper J, Brase c, glien a, Kühnemund 
M, Koscielny S, Schwerdtfeger P, Välimäki M, Szyfter W, Finckh U, Zerres K, cascon a, 
Opocher g, ridder gJ, Januszewicz a, Suarez c, eng c. clinical predictors for germline 
group.bmj.com on March 20, 2018 - Published by http://jmg.bmj.com/Downloaded from 
11Andrews KA, et al. J Med Genet 2018;0:1–11. doi:10.1136/jmedgenet-2017-105127
Cancer genetics
mutations in head and neck paraganglioma patients: cost reduction strategy in 
genetic diagnostic process as fall-out. Cancer Res 2009;69:3650–6.
 30 Bayley JP, grimbergen ae, van Bunderen Pa, van der Wielen M, Kunst HP, lenders JW, 
Jansen Jc, Dullaart rP, Devilee P, corssmit eP, Vriends aH, losekoot M, Weiss MM. the 
first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients. 
BMC Med Genet 2009;10:34.
 31 Hensen eF, van Duinen n, Jansen Jc, corssmit eP, tops cM, romijn Ja, Vriends aH, 
van der Mey ag, cornelisse cJ, Devilee P, Bayley JP. High prevalence of founder 
mutations of the succinate dehydrogenase genes in the netherlands. Clin Genet 
2012;81:284–8.
 32 Jubb Hc, Higueruelo aP, Ochoa-Montaño B, Pitt Wr, ascher DB, Blundell tl. arpeggio: 
a Web Server for calculating and Visualising interatomic interactions in Protein 
Structures. J Mol Biol 2017;429:365–71.
 33 Jochmanova i, Wolf Ki, King KS, nambuba J, Wesley r, Martucci V, raygada M, adams 
Kt, Prodanov t, Fojo at, lazurova i, Pacak K. SDHB-related pheochromocytoma and 
paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin 
Oncol 2017;143:1421–35.
 34 Baysal Be, Willett-Brozick Je, Filho Pa, lawrence ec, Myers en, Ferrell re. an alu-
mediated partial SDHc deletion causes familial and sporadic paraganglioma. J Med 
Genet 2004;41:703–9.
 35 Schiavi F, Boedeker cc, Bausch B, Peçzkowska M, gomez cF, Strassburg t, Pawlu c, 
Buchta M, Salzmann M, Hoffmann MM, Berlis a, Brink i, cybulla M, Muresan M, 
Walter Ma, Forrer F, Välimäki M, Kawecki a, Szutkowski Z, Schipper J, Walz MK, Pigny 
P, Bauters c, Willet-Brozick Je, Baysal Be, Januszewicz a, eng c, Opocher g, neumann 
HP; european-american Paraganglioma Study group. Predictors and prevalence 
of paraganglioma syndrome associated with mutations of the SDHc gene. JAMA 
2005;294:2057–63.
 36 Bickmann JK, Sollfrank S, Schad a, Musholt tJ, Springer e, Miederer M, Bartsch 
O, Papaspyrou K, Koutsimpelas D, Mann WJ, Weber MM, lackner KJ, rossmann 
H, Fottner c. Phenotypic variability and risk of malignancy in SDHc-linked 
paragangliomas: lessons from three unrelated cases with an identical germline 
mutation (p.arg133*). J Clin Endocrinol Metab 2014;99:e489–e496.
 37 Bourdeau i, grunenwald S, Burnichon n, Khalifa e, Dumas n, Binet Mc, nolet S, 
gimenez-roqueplo aP. a SDHc Founder Mutation causes Paragangliomas (Pgls) 
in the French canadians: new insights on the SDHc-related Pgl. J Clin Endocrinol 
Metab 2016;101:4710–8.
 38 lefebvre M, Foulkes WD. Pheochromocytoma and paraganglioma syndromes: genetics 
and management update. Curr Oncol 2014;21:8.
 39 Bayley JP, Oldenburg ra, nuk J, Hoekstra aS, van der Meer ca, Korpershoek e, 
Mcgillivray B, corssmit eP, Dinjens Wn, de Krijger rr, Devilee P, Jansen Jc, Hes 
FJ. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD 
mutations. BMC Med Genet 2014;15:111.
 40 Burnichon n, Mazzella JM, Drui D, amar l, Bertherat J, coupier i, Delemer B, guilhem 
i, Herman P, Kerlan V, tabarin a, Wion n, lahlou-laforet K, Favier J, gimenez-
roqueplo aP. risk assessment of maternally inherited SDHD paraganglioma and 
phaeochromocytoma. J Med Genet 2017;54.
 41 Dahia Pl, ross Kn, Wright Me, Hayashida cY, Santagata S, Barontini M, Kung al, 
Sanso g, Powers JF, tischler aS, Hodin r, Heitritter S, Moore F, Dluhy r, Sosa Ja, Ocal 
it, Benn De, Marsh DJ, robinson Bg, Schneider K, garber J, arum SM, Korbonits 
M, grossman a, Pigny P, toledo SP, nosé V, li c, Stiles cD. a HiF1alpha regulatory 
loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 
2005;1:e8–80.
 42 Pollard PJ, Brière JJ, alam na, Barwell J, Barclay e, Wortham nc, Hunt t, Mitchell 
M, Olpin S, Moat SJ, Hargreaves iP, Heales SJ, chung Yl, griffiths Jr, Dalgleish 
a, Mcgrath Ja, gleeson MJ, Hodgson SV, Poulsom r, rustin P, tomlinson iP. 
accumulation of Krebs cycle intermediates and over-expression of HiF1alpha 
in tumours which result from germline FH and SDH mutations. Hum Mol Genet 
2005;14:2231–9.
 43 lópez-Jiménez e, gómez-lópez g, leandro-garcía lJ, Muñoz i, Schiavi F, Montero-
conde c, de cubas aa, ramires r, landa i, leskelä S, Maliszewska a, inglada-Pérez 
l, de la Vega l, rodríguez-antona c, letón r, Bernal c, de campos JM, Diez-tascón 
c, Fraga MF, Boullosa c, Pisano Dg, Opocher g, robledo M, cascón a. research 
resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB 
and VHl-related pheochromocytomas. Mol Endocrinol 2010;24:2382–91.
 44 Morin a, letouzé e, gimenez-roqueplo aP, Favier J. Oncometabolites-driven 
tumorigenesis: From genetics to targeted therapy. Int J Cancer 2014;135:2237–48.
 45 Sun F, Huo X, Zhai Y, Wang a, Xu J, Su D, Bartlam M, rao Z. crystal structure of 
mitochondrial respiratory membrane protein complex ii. Cell 2005;121:1043–57.
 46 Panizza e, ercolino t, Mori l, rapizzi e, castellano M, Opocher g, Ferrero i, neumann 
HP, Mannelli M, goffrini P. Yeast model for evaluating the pathogenic significance 
of SDHB, SDHc and SDHD mutations in PHeO-Pgl syndrome. Hum Mol Genet 
2013;22:804–15.
 47 Kiuru M, Vanharanta S, Virta SK, Buchta M, McWhinney Sr, aaltonen la, neumann 
HP, eng c. early-onset renal cell carcinoma caused by germline mutations in SDHB as 
a novel component of inherited paraganglioma syndrome. Cancer Res 2004;64:524.
 48 Pasini B, McWhinney Sr, Bei t, Matyakhina l, Stergiopoulos S, Muchow M, Boikos Sa, 
Ferrando B, Pacak K, assie g, Baudin e, chompret a, ellison JW, Briere JJ, rustin P, 
gimenez-roqueplo aP, eng c, carney Ja, Stratakis ca. clinical and molecular genetics 
of patients with the carney-Stratakis syndrome and germline mutations of the genes 
coding for the succinate dehydrogenase subunits SDHB, SDHc, and SDHD. Eur J Hum 
Genet 2008;16:79–88.
 49 Janeway Ka, Kim SY, lodish M, nosé V, rustin P, gaal J, Dahia Pl, liegl B, Ball er, 
raygada M, lai aH, Kelly l, Hornick Jl, O’Sullivan M, de Krijger rr, Dinjens Wn, 
Demetri gD, antonescu cr, Fletcher Ja, Helman l, Stratakis ca; niH Pediatric 
and Wild-type giSt clinic. Defects in succinate dehydrogenase in gastrointestinal 
stromal tumors lacking Kit and PDgFra mutations. Proc Natl Acad Sci U S A 
2011;108:314–8.
 50 ni Y, Seballos S, ganapathi S, gurin D, Fletcher B, ngeow J, nagy r, Kloos rt, ringel 
MD, laFramboise t, eng c. germline and somatic SDHx alterations in apparently 
sporadic differentiated thyroid cancer. Endocr Relat Cancer 2015;22:121–30.
 51 Dénes J, Swords F, rattenberry e, Stals K, Owens M, cranston t, Xekouki P, Moran 
l, Kumar a, Wassif c, Fersht n, Baldeweg Se, Morris D, lightman S, agha a, rees 
a, grieve J, Powell M, Boguszewski cl, Dutta P, thakker rV, Srirangalingam U, 
thompson cJ, Druce M, Higham c, Davis J, eeles r, Stevenson M, O’Sullivan B, taniere 
P, Skordilis K, gabrovska P, Barlier a, Webb SM, aulinas a, Drake WM, Bevan JS, 
Preda c, Dalantaeva n, ribeiro-Oliveira a, garcia it, Yordanova g, iotova V, evanson 
J, grossman aB, trouillas J, ellard S, Stratakis ca, Maher er, roncaroli F, Korbonits 
M. Heterogeneous genetic background of the association of pheochromocytoma/
paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin 
Endocrinol Metab 2015;100:e531–e541.
 52 Solis Dc, Burnichon n, timmers HJ, raygada MJ, Kozupa a, Merino MJ, Makey 
D, adams Kt, Venisse a, gimenez-roqueplo aP, Pacak K. Penetrance and 
clinical consequences of a gross SDHB deletion in a large family. Clin Genet 
2009;75:354–63.
 53 Hes FJ, Weiss MM, Woortman Sa, de Miranda nF, van Bunderen Pa, Bonsing Ba, 
Stokkel MP, Morreau H, romijn Ja, Jansen Jc, Vriends aH, Bayley JP, corssmit eP. low 
penetrance of a SDHB mutation in a large Dutch paraganglioma family. BMC Med 
Genet 2010;11:92.
 54 rijken Ja, niemeijer nD, corssmit eP, Jonker Ma, leemans cr, Menko FH, Hensen eF. 
low penetrance of paraganglioma and pheochromocytoma in an extended kindred 
with a germline SDHB exon 3 deletion. Clin Genet 2016;89:128–32.
 55 rijken Ja, niemeijer nD, Jonker Ma, eijkelenkamp K, Jansen Jc, van Berkel a, timmers 
H, Kunst HPM, Bisschop P, Kerstens Mn, Dreijerink KMa, van Dooren MF, van der 
Horst-Schrivers ana, Hes FJ, leemans cr, corssmit ePM, Hensen eF. the penetrance 
of paraganglioma and pheochromocytoma in SDHB germline mutation carriers. Clin 
Genet 2018;93.
 56 lenders JW, Duh QY, eisenhofer g, gimenez-roqueplo aP, grebe SK, Murad 
MH, naruse M, Pacak K, Young WF, Pheochromocytoma YWF; endocrine Society. 
Pheochromocytoma and paraganglioma: an endocrine society clinical practice 
guideline. J Clin Endocrinol Metab 2014;99:1915–42.
 57 lepoutre-lussey c, caramella c, Bidault F, Déandreis D, Berdelou a, al ghuzlan 
a, Hartl D, Borget i, gimenez-roqueplo aP, Dumont F, Deschamps F, nascimento 
c, lumbroso J, guillaud Bataille M, Schlumberger M, Baudin e, leboulleux S. 
Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDg 
Pet/ct at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging 
2015;42:868–76.
 58 tufton n, Shapiro l, Srirangalingam U, richards P, Sahdev a, Kumar aV, Mcandrew 
l, Martin l, Berney D, Monson J, chew Sl, Waterhouse M, Druce M, Korbonits M, 
Metcalfe K, Drake WM, Storr Hl, akker Sa. Outcomes of annual surveillance imaging 
in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. Clin 
Endocrinol 2017;86:286–96.
 59 Bayley JP, Devilee P, taschner Pe. the SDH mutation database: an online resource 
for succinate dehydrogenase sequence variants involved in pheochromocytoma, 
paraganglioma and mitochondrial complex ii deficiency. BMC Med Genet 2005;6:39.
 60 Meyer-rochow gY, Smith JM, richardson al, Marsh DJ, Sidhu SB, robinson Bg, Benn 
De. Denaturing high performance liquid chromatography detection of SDHB, SDHD, 
and VHl germline mutations in pheochromocytoma. J Surg Res 2009;157:55–62.
 61 exome aggregation consortium (exac). ExAC Browser (Beta) | Exome Aggregation 
Consortium. cambridge, Ma. http:// exac. broadinstitute. org
group.bmj.com on March 20, 2018 - Published by http://jmg.bmj.com/Downloaded from 
SDHD and SDHC, SDHBgenes 
variants in succinate dehydrogenase subunit
correlations associated with germline 
phenotype−Tumour risks and genotype
Eamonn R Maher
Lindsay, Colin G Perry, Emma R Woodward, Antonis C Antoniou and 
Susan E Tomkins, Yvonne Wallis, Louise Izatt, David Goudie, Robert S
Murday, Soo-Mi Park, Helen L Simpson, Katie Snape, Susan Stewart, 
McConachie, Vivienne P M McConnell, Patrick J Morrison, Victoria
Greenhalgh, Shirley V hodgson, Richard Irving, Fiona Lalloo, Michelle 
A Cook, Rosemarie Davidson, Alan Donaldson, Alan Fryer, Lynn
Adlard, Simon Aylwin, Paul Brennan, Carole Brewer, Trevor Cole, Jackie 
JulianDaniel R Barnes, Lindsey Vialard, Ruth T Casey, Nicola Bradshaw, 
Katrina A Andrews, David B Ascher, Douglas Eduardo Valente Pires,
 published online January 31, 2018J Med Genet
 http://jmg.bmj.com/content/early/2018/01/31/jmedgenet-2017-105127
Updated information and services can be found at: 
These include:
References
 #ref-list-1
http://jmg.bmj.com/content/early/2018/01/31/jmedgenet-2017-105127
This article cites 57 articles, 7 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (208)Open access
 (1255)Molecular genetics
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on March 20, 2018 - Published by http://jmg.bmj.com/Downloaded from 
